Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma
Authors:
- Ramin Raul Ossami SaidyRamin Raul Ossami Saidy
- Maximilian Paul PostelMPMaximilian Paul Postel
- Michael Johannes PflügerMPMichael Johannes Pflüger
- Wenzel SchoeningWSWenzel Schoening
- Robert ÖllingerRobert Öllinger
- Safak Gül-KleinSGSafak Gül-Klein
- Moritz SchmelzleMSMoritz Schmelzle
- Frank TackeFrank Tacke
- Johann PratschkeJPJohann Pratschke
- Dennis EurichDennis Eurich
Open Access
Abstract
Introduction: Recurrence of hepatocellular carcinoma (rHCC) after liver transplantation (LT) is associated with limited survival. Therefore, identification of factors that prolong survival in these patients is of great interest. Surgical resection, radiotherapy, and transarterial chemoembolization (TACE) are established interventions to improve outcomes in these patients; however, the impact of immunosuppression is unknown. Methods: All patients diagnosed with rHCC in the follow-up after LT were identified from a database of liver recipients transplanted between 1988 and 2019 at our institution (Charité Universitätsmedizin Berlin, Germany). Based on the immunosuppressive regimen following diagnosis of rHCC and the oncological treatment approach, survival analysis was performed. Results: Among 484 patients transplanted for HCC, 112 (23.1%) developed rHCC in the follow-up. Recurrent HCC was diagnosed at a median interval of 16.0 months (range 1.0–203.0), with the majority presenting early after transplantation (63.0%, n = 7, 6.8%) and did not result in any graft loss. Patients that underwent surgical resection showed improved survival rates (median 19.5 vs. 8.7 months). Conclusion: Reduction of immunosuppressive therapy after rHCC diagnosis is associated with prolonged survival in LT patients. Therefore, reduction of immunosuppression should be an early intervention following diagnosis. In addition, surgical resection should be attempted, if technically feasible and oncologically meaningful.Keywords
This publication has 35 references indexed in Scilit:
- Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus ConferenceTransplantation, 2020
- Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence SurvivalTransplantation, 2020
- Liver transplantation for hepatocellular carcinoma: Management after the transplantAmerican Journal of Transplantation, 2019
- Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?Translational Gastroenterology and Hepatology, 2017
- Sirolimus Use in Liver Transplant Recipients With Hepatocellular CarcinomaTransplantation, 2016
- Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic reviewWorld Journal of Gastroenterology, 2015
- Review on immunosuppression in liver transplantationWorld Journal of Hepatology, 2015
- Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantationLiver Transplantation, 2014
- Effect of Different Immunosuppressive Schedules on Recurrence-Free Survival After Liver Transplantation for Hepatocellular CarcinomaTransplantation, 2010
- Grading and staging systems for inflammation and fibrosis in chronic liver diseasesJournal of Hepatology, 2007